As the unintelligible battle rages on YMB…

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
biopearl123
Posts: 1665
Joined: Fri Jul 20, 2018 5:13 pm

As the unintelligible battle rages on YMB…

Post by biopearl123 » Fri Dec 02, 2022 8:53 pm

It is important to return to basics. Dr. Steensma’s (et.al) presentation at 2018 ASH preceded the subsequent excellent publication in the Journal of Clinical Oncology Oct 27, 2020. This presentation addresses the SF3B1 data if anyone is interested in what it actually is. Also slide 9 of the 2018 ASH meeting presentation shows that every single patient in the 38 patient subgroup except one had a reduction in transfusion burden. A handful showed a decrease in transfusion burden of less than 4 units/per eight weeks and were not considered with the greater than four transfusion group as significant. But visit the slide. Every patient but one improved. Yes it’s possible that those on the low end of improvement (some by one, two or three) transfusions/8weeks improved by chance, but only one got worse. Worth a re visit.

https://www.geron.com/file.cfm/53/docs/ ... 0FINAL.pdf

Post Reply